Vivanta Industries Limited has rescheduled its Board of Directors meeting to July 29, 2026, originally set for July 24, 2026, due to heavy rainfall and prevailing adverse weather conditions. The company informed the Bombay Stock Exchange (BSE) on July 24, 2026, that the postponement was necessary to ensure the smooth conduct of proceedings under Regulation 29(1)(a) and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The primary objective of the rescheduled meeting remains the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report. This delay impacts the timeline for the declaration of Q1FY26 results, which are critical for investors assessing the company's performance following the fiscal year ended March 31, 2026.

Key Agenda Items

Beyond the quarterly results, the Board will address several other material matters during the July 29 session:

• FY26 Audited Statements: Authorization of signatories for signing the audited financial statements for the financial year ended March 31, 2026.
• Business Collaboration: Taking note of certain business collaboration agreements with Qness Pharmaceuticals, a proprietorship concern involved in the manufacture, supply, branding, and marketing of pharmaceutical and allied products.
• Corporate Governance: Review of the Corporate Governance Report for the quarter ended June 30, 2026.
• Deposit Returns: Note of the E-Form DPT-3 Return of Deposits for the quarter ended June 30, 2026.
• Share Certificates: Issuance of duplicate share certificates in lieu of originals reported as lost or misplaced by shareholders.

Regulatory Compliance and Trading Window

The company stated that the notice for the Board meeting will be made available on its website in compliance with Regulation 46 of the SEBI Listing Regulations. Furthermore, Vivanta Industries confirmed that the trading window for dealing in the company's securities by Directors, Officers, Key Managerial Personnel, and Designated Persons remains closed. This restriction, mandated under the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s Internal Code, will remain in effect until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.

What the Numbers Show

While specific financial figures for Q1FY26 are not yet disclosed due to the meeting reschedule, the inclusion of a collaboration with Qness Pharmaceuticals suggests a strategic focus on expanding its pharmaceutical portfolio. The timing of this announcement alongside the quarterly results indicates that management views this partnership as a significant operational development for the upcoming fiscal period. Investors should monitor the final approved results for any impact from this new collaboration.

Vivanta Industries has submitted its audited financial results for the quarter and year ended March 31, 2026, confirming compliance with regulatory disclosure requirements. The statutory auditors, M/S. GMCA & CO, Chartered Accountants, Ahmedabad, have issued an audit report with an unmodified opinion on the company's financial performance for the period.

The declaration was made in compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the submission of audited results to the stock exchanges to ensure transparency and adherence to disclosure norms.

The audit report covers the financial statements for the full fiscal year ending March 31, 2026. An unmodified opinion indicates that the auditors found the financial statements to be free of material misstatements and prepared in accordance with the applicable accounting standards.

Key Details of the Filing

The filing was submitted to BSE Limited on July 1, 2026, by H. A. Parikh, Managing Director of Vivanta Industries. The submission ensures that the audited financial results are available on the public record for shareholders and regulatory bodies.